Publications by authors named "Caron A Jacobson"

Claim this Profile
T
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph, Esther Drill, Suheil Albert Atallah-Yunes, Caron A Jacobson

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L Ulrickson, Caron A Jacobson

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Caron A Jacobson, Jason R Westin, David B Miklos, Alex F Herrera, Jerome Ritz

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma.
J Erika Haydu, Robert A Redd, Matthew M Lei, Ephraim Hochberg, Jeffrey A Barnes, Caron A Jacobson

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.
Soumya Poddar, Jiali Yan, Gayatri Tiwari, Darawan Rinchai, Justin Budka, Caron A Jacobson

J Clin Invest· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies.
Katie Maurer, Caron A Jacobson

Leuk Lymphoma· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.
Mwanasha H Merrill, Robert A Redd, David C Fisher, Jeremy S Abramson, Jeffrey Barnes, Caron A Jacobson

Leuk Lymphoma· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CAR enhancer increases the activity and persistence of CAR T cells.
Taha Rakhshandehroo, Shreya R Mantri, Heydar Moravej, Benjamin B V Louis, Ali Salehi Farid, Caron A Jacobson

Nat Biotechnol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sarah Nikiforow, Sairah Ahmed

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S Choi, Stacey M Fernandes, Caron A Jacobson

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.
Matthew J Frigault, Ning Yao, Trisha R Berger, Marc Wehrli, Kathleen M E Gallagher, Caron A Jacobson

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study.
Kathleen M M Vanni, Kaitlin R McCarter, Xiaosong Wang, Caitlyn Duffy, Jamie P Dela Cruz, Caron A Jacobson

Lancet Rheumatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva, Caron A Jacobson

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva, Caron A Jacobson

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Andrew Looka, David A Qualls, Daniel Matthews, Robert A Redd, Christopher Sakellis, Caron A Jacobson

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Daniel J Landsburg, Matthew J Frigault, Michael Heim, Stephen Ronan Foley, Brian Hill, Caron A Jacobson

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy.
P Connor Johnson, Jeremy S Abramson, Ann S LaCasce, Philippe Armand, Jeffrey Barnes, Caron A Jacobson

J Natl Compr Canc Netw· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Jon E Arnason, Adam M Boruchov, Caron A Jacobson

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Lazaros J Lekakis, Caron A Jacobson

Transplant Cell Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Hazim S Ababneh, Andrea K Ng, Matthew J Frigault, Caron A Jacobson, Chirayu G Patel

Am J Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disseminated Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma.
Jessica S Little, Rocio M Hurtado, Nicholas Boire, Lindsey R Baden, Alvaro C Laga, Caron A Jacobson

Open Forum Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States.
Olalekan O Oluwole, Markqayne D Ray, Katherine L Rosettie, Graeme Ball, Jorge Jacob, Caron A Jacobson

Value Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot data on axicabtagene ciloleucel for CNS lymphoma.
Caron A Jacobson

Clin Adv Hematol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis